| LUDWIG, H., M.A. DIMOPOULOS, P. MOREAU, W.J. CHNG, H. GOLDSCHMIDT, Roman HÁJEK, T. FACON, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSINOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, A. PALUMBO, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S.B. FENG and D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2017, vol. 58, No 10, p. 2501-2504. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2017.1298755. |
Other formats:
BibTeX
LaTeX
RIS
@article{1398977,
author = {Ludwig, H. and Dimopoulos, M.A. and Moreau, P. and Chng, W.J. and Goldschmidt, H. and Hájek, Roman and Facon, T. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosinol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Palumbo, A. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S.B. and Joshua, D.},
article_location = {LONDON},
article_number = {10},
doi = {http://dx.doi.org/10.1080/10428194.2017.1298755},
keywords = {Carfilzomib; dexamethasone; bortezomib},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
title = {Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup},
url = {http://dx.doi.org/10.1080/10428194.2017.1298755},
volume = {58},
year = {2017}
}
TY - JOUR
ID - 1398977
AU - Ludwig, H. - Dimopoulos, M.A. - Moreau, P. - Chng, W.J. - Goldschmidt, H. - Hájek, Roman - Facon, T. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosinol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Palumbo, A. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S.B. - Joshua, D.
PY - 2017
TI - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
JF - LEUKEMIA & LYMPHOMA
VL - 58
IS - 10
SP - 2501-2504
EP - 2501-2504
PB - INFORMA HEALTHCARE
SN - 10428194
KW - Carfilzomib
KW - dexamethasone
KW - bortezomib
UR - http://dx.doi.org/10.1080/10428194.2017.1298755
L2 - http://dx.doi.org/10.1080/10428194.2017.1298755
N2 - Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
ER -
LUDWIG, H., M.A. DIMOPOULOS, P. MOREAU, W.J. CHNG, H. GOLDSCHMIDT, Roman HÁJEK, T. FACON, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSINOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, A. PALUMBO, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S.B. FENG and D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2017, vol.~58, No~10, p.~2501-2504. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2017.1298755.
|
